CN Patent

CN111433375B — 选择针对癌症患者的治疗的方法

Assigned to Novartis AG · Expires 2024-07-30 · 2y expired

What this patent protects

本公开涉及用于治疗患有癌症例如乳腺癌的患者的新颖预测方法和个性化疗法。具体地，本公开涉及通过选择性施用CDK 4/6抑制剂和来曲唑的组合来治疗患有癌症的患者的方法。本文还公开了可用于预测患有癌症例如乳腺癌的患者将对CDK 4/6抑制剂例如瑞博西尼和芳香酶抑制剂来曲唑的组合治疗产生应答的可能性的可传输形式信息、诊断方法和试剂盒。

USPTO Abstract

本公开涉及用于治疗患有癌症例如乳腺癌的患者的新颖预测方法和个性化疗法。具体地，本公开涉及通过选择性施用CDK 4/6抑制剂和来曲唑的组合来治疗患有癌症的患者的方法。本文还公开了可用于预测患有癌症例如乳腺癌的患者将对CDK 4/6抑制剂例如瑞博西尼和芳香酶抑制剂来曲唑的组合治疗产生应答的可能性的可传输形式信息、诊断方法和试剂盒。

Drugs covered by this patent

ribociclib-succinate (RIBOCICLIB SUCCINATE)

Patent Metadata

Patent number: CN111433375B
Jurisdiction: CN
Classification: —
Expires: 2024-07-30
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.